Elevated C-Reactive Protein Linked with Poor Prognosis in Prostate Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the European Journal of Cancer, researchers have found that an elevated c-reactive protein level is associated with poor prognosis in treated patients with prostate cancer.

C-reactive protein is a biomarker of inflammation that has been associated with prognosis in numerous solid tumors.

For this study, researchers sought to investigate whether or not a c-reactive protein is associated with prognosis in patients with prostate cancer treated with radiation. Researchers enrolled 261 patients with prostate cancer who were treated with 3D-conformal radiotherapy and were followed for a median duration of 80 months.

Researchers determined that the optimal cut-off level for plasma c-reactive protein was 8.6mgl-1. Multivariate analyses showed that an elevated c-reactive protein level was linked with decreased cancer specific survival (HR = 4.31; 95% CI: 1.22 - 15.1; P = 0.023).

In addition, results showed an association between an elevated c-reactive protein level and decreased overall survival (HR = 3.24; 95% CI: 1.84 - 5.71; P < 0.001), and clinical disease-free survival (HR = 2.07; 95% CI: 1.02 - 4.17; P = 0.043).

The findings suggest that an elevated plasma c-reactive protein level of 8.6mgl-1 is associated with a poor prognosis, but additional studies are warranted to confirm the results.

Radiotherapy Following Prostatectomy May Have Lasting Benefits
An elevated c-reactive protein level is associated with poor prognosis in treated patients with prostate cancer.
In the present study, the authors analysed the prognostic relevance of elevated plasma CRP levels in prostate cancer patients treated with radiotherapy. In the present study, an elevated plasma CRP has been identified as a prognostic factor for poor CSS, OS and DFS in prostate cancer patients undergoing radiotherapy.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs